OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
June 04, 2020
Agreements with the PolyPeptide Group and AGC Biologics will scale up production of the Novavax Matrix-M adjuvant.
February 15, 2020
Technology and capacity investments create opportunities in the cell and gene therapy arena for CDMOs and biopharma alike.
February 01, 2020
CDMOs and CMOs will continue to invest in biopharmaceutical services and facilities as the bio/pharmaceutical industry looks to biosimilars and personalized medicine.
August 01, 2019
Successful process intensification with inline dilution requires effective monitoring and control.
June 20, 2019
The company has expanded its high-potency API capability at its Riverview, MI, facility to serve the growing antibody drug conjugates market.
June 05, 2019
CDMO iBio introduced cGMP sterile fill/finish services at its facility in Texas.
May 16, 2019
The acquisition of GlaxoSmithKline’s manufacturing site in Cork, Ireland, will expand Thermo Fisher Scientific’s global footprint for complex API manufacturing.
March 19, 2019
A $100-million investment will expand a range of the CDMO’s service capabilities and offerings.
November 26, 2018
ADC Biotechnology will invest downstream formulation, fill/finish capabilities, and Lock-Release conjugation technology.
October 01, 2018
The maturation of single-use technologies presents commercial bioprocessing options for small-volume drug products.